Compare Merck & Co., Inc. (MRK) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Merck & Co., Inc. trades at $148.1 (market cap $366.28B), while Vanguard Total Stock Market Index Fund ETF trades at $376.74. The key difference: Merck & Co., Inc. pays a 2.29% dividend while Vanguard Total Stock Market Index Fund ETF pays none. Which is the better fit depends on your goals.
| MRK | VTI | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | — |
52-Week High | $156.43 | $384.30 |
52-Week Low | $77.60 | $311.68 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
VTI trades at $377.60, down 0.56% with neutral technical signals. The ETF maintains broad U.S. market exposure across 3,515 stocks with a minimal 0.03% expense ratio. Recent institutional activity includes DMC Group's $794,000 investment in Q2 2026, while technical indicators show support at $375 and resistance at $379.
Long-term outlook remains positive given historical 10% annual market returns, though concentration risk exists with top ten holdings representing one-third of assets. Market sentiment favors VTI for diversification amid potential volatility, with analysts highlighting its core portfolio role for 20-year horizons.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
